Rise Advisors’s Precision BioSciences DTIL Stock Holding History

Rise Advisors’s Portfolio DTIL Stock Details DTIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-206	Closed	-$1.14K	–	484
2025 Q3	$1.14K	Buy	+206	New	+$986	﹤0.01%	1263

Other funds holding DTIL

EAM

Empery Asset Management New York $83M AUM

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Rise Advisors's DTIL Position: Q4 2025 in Review

Rise Advisors sold out of Precision BioSciences (DTIL) in Q4 2025, closing a stake of 206 shares — an estimated $1.14K sold.

Rise Advisors first reported a position in DTIL in Q3 2025 and held it in 1 quarter. The position peaked at $1.14K in Q3 2025. 69 funds tracked by Wall St. Rank hold DTIL as of Q4 2025.

Rise Advisors reported no remaining Precision BioSciences position as of Q4 2025 after selling out during the quarter.
Rise Advisors sold 206 Precision BioSciences shares in Q4 2025, an estimated $1.14K.
Rise Advisors first reported a position in Precision BioSciences in Q3 2025 and held it in 1 quarter.
Rise Advisors's Precision BioSciences position peaked at $1.14K in Q3 2025.
69 funds tracked by Wall St. Rank held Precision BioSciences as of Q4 2025.

Based on Rise Advisors's 13F filing for Q4 2025, filed 11 Feb 2026.